MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Free Report) – Equities research analysts at Diamond Equity reduced their Q3 2026 earnings per share estimates for shares of MAIA Biotechnology in a report issued on Monday, August 17th. Diamond Equity analyst H. Diamond now expects that the company will post earnings of ($0.13) per share for the quarter, down from their prior estimate of ($0.12). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($0.52) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.54) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.48) EPS.
MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02).
MAIA Biotechnology Stock Performance
Hedge Funds Weigh In On MAIA Biotechnology
Hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP purchased a new position in shares of MAIA Biotechnology in the second quarter worth $29,000. PVG Asset Management Corp purchased a new stake in MAIA Biotechnology in the 1st quarter worth approximately $46,000. Jane Street Group LLC purchased a new stake in MAIA Biotechnology during the second quarter worth $52,000. Corsair Capital Management L.P. acquired a new stake in shares of MAIA Biotechnology during the 1st quarter valued at about $140,000. Finally, Geode Capital Management LLC grew its holdings in MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after purchasing an additional 7,746 shares during the period. 5.65% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, CEO Vlad Vitoc bought 72,700 shares of the stock in a transaction on Monday, June 1st. The stock was acquired at an average cost of $1.39 per share, for a total transaction of $101,053.00. Following the acquisition, the chief executive officer owned 976,121 shares of the company’s stock, valued at $1,356,808.19. This represents a 8.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stan Smith acquired 75,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were acquired at an average price of $1.34 per share, for a total transaction of $100,500.00. Following the completion of the purchase, the director owned 1,519,178 shares of the company’s stock, valued at approximately $2,035,698.52. This represents a 5.19% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 149,700 shares of company stock valued at $204,233. 19.81% of the stock is currently owned by corporate insiders.
About MAIA Biotechnology
MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.
The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.
Featured Articles
- Five stocks we like better than MAIA Biotechnology
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
